Jefferies Upgrades Moderna to Buy, Raises Price Target to $275
Jefferies analyst Michael Yee upgrades Moderna (NASDAQ:MRNA) from Hold to Buy and raises the price target from $170 to $275.
JP Morgan Upgrades Glaukos to Neutral, Lowers Price Target to $42
JP Morgan analyst Allen Gong upgrades Glaukos (NYSE:GKOS) from Underweight to Neutral and lowers the price target from $48 to $42.
OTR Global Upgrades United Rentals to Positive
OTR Global upgrades United Rentals (NYSE:URI) from Mixed to Positive.
CIBC Upgrades HEXO to Neutral
CIBC analyst John Zamparo upgrades HEXO (TSX:HEXO) from Underperformer to Neutral.
UBS Upgrades Sarepta Therapeutics to Buy, Raises Price Target to $158
UBS analyst Colin Bristow upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Buy and raises the price target from $100 to $158.
Wells Fargo Upgrades Pembina Pipeline to Overweight, Raises Price Target to C$53
Wells Fargo analyst Praneeth Satish upgrades Pembina Pipeline (TSX:PPL) from Equal-Weight to Overweight and raises the price target from C$46 to C$53.
Wells Fargo Upgrades ONEOK to Overweight, Raises Price Target to $75
Wells Fargo analyst Michael Blum upgrades ONEOK (NYSE:OKE) from Equal-Weight to Overweight and raises the price target from $68 to $75.
Wells Fargo Upgrades Ryan Specialty Holdings to Overweight, Raises Price Target to $45
Wells Fargo analyst Elyse Greenspan upgrades Ryan Specialty Holdings (NYSE:RYAN) from Equal-Weight to Overweight and raises the price target from $41 to $45.
Wells Fargo Upgrades Crestwood Equity Partners to Overweight, Announces $35 Price Target
Wells Fargo analyst Ned Baramov upgrades Crestwood Equity Partners (NYSE:CEQP) from Equal-Weight to Overweight and announces $35 price target.
BTIG Upgrades Agilysys to Buy
BTIG analyst Matthew Vanvliet upgrades Agilysys (NASDAQ:AGYS) from Neutral to Buy.